BetaGlue® Completes Exclusive Global Agreement With ArtivionTM Securing Supply Of BioGlue® For The Manufacture Of BetaGlue’s YntraDose® Oncology Platform
Milan, February 20th 2025 – BetaGlue® Therapeutics S.p.A. (“BetaGlue”), a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called YntraDose®,…
Read more











